B. Riley Analysts Boost Earnings Estimates for Novavax

Novavax, Inc. (NASDAQ:NVAX) – Stock analysts at B. Riley upped their Q2 2025 earnings per share estimates for shares of Novavax in a note issued to investors on Thursday, February 20th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings per share of $0.67 for the quarter, up from their prior estimate of $0.65. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax’s FY2026 earnings at $2.05 EPS, FY2027 earnings at $1.49 EPS, FY2028 earnings at $0.96 EPS and FY2029 earnings at $1.62 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $17.83.

Novavax Trading Up 0.9 %

Shares of NASDAQ NVAX opened at $7.99 on Friday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -3.54, a P/E/G ratio of 2.85 and a beta of 2.14. Novavax has a 1-year low of $3.81 and a 1-year high of $23.86. The stock’s 50-day moving average is $8.65 and its 200 day moving average is $10.11.

Insiders Place Their Bets

In other Novavax news, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the transaction, the director now directly owns 14,770 shares of the company’s stock, valued at $133,225.40. The trade was a 21.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James F. Young sold 4,600 shares of Novavax stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total value of $39,008.00. Following the completion of the transaction, the director now directly owns 57,160 shares in the company, valued at $484,716.80. This trade represents a 7.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,150 shares of company stock valued at $119,641 in the last ninety days. Company insiders own 1.00% of the company’s stock.

Institutional Investors Weigh In On Novavax

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Novavax by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company’s stock worth $126,439,000 after buying an additional 296,181 shares during the last quarter. Shah Capital Management grew its position in shares of Novavax by 13.6% in the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after buying an additional 1,333,305 shares during the last quarter. State Street Corp grew its position in shares of Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after buying an additional 1,621,772 shares during the last quarter. Sanofi bought a new stake in shares of Novavax in the 4th quarter worth approximately $55,319,000. Finally, Geode Capital Management LLC grew its position in shares of Novavax by 4.4% in the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company’s stock worth $29,415,000 after buying an additional 155,206 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.